Literature DB >> 3822305

Major morbidity after pelvic exenteration: a seven-year experience.

W S Roberts, D Cavanagh, S C Bryson, G H Lyman, S Hewitt.   

Abstract

Thirty-eight patients underwent pelvic exenteration at the University of South Florida during the last seven years. The majority of the operations were performed for recurrent carcinoma of the cervix, and the operative mortality was 5.3%. Twenty-one patients developed major morbidity in the postoperative period, and 11 with complications involving the gastrointestinal or urinary tract required reoperation. Multivariate logistic regression analysis demonstrated a correlation between the amount of pelvic radiation, type of pelvic floor, type of pelvic drain, amount of blood loss, race, and the occurrence of serious postoperative morbidity. Strategies to avoid serious postoperative morbidity are discussed.

Entities:  

Mesh:

Year:  1987        PMID: 3822305

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  4 in total

Review 1.  The role of palliative surgery in gynecologic cancer cases.

Authors:  Joanie Mayer Hope; Bhavana Pothuri
Journal:  Oncologist       Date:  2013-01-08

2.  Major complications following exenteration in cases of pelvic malignancy: a 10-year experience.

Authors:  Dariusz Wydra; Janusz Emerich; Sambor Sawicki; Katarzyna Ciach; Andrzej Marciniak
Journal:  World J Gastroenterol       Date:  2006-02-21       Impact factor: 5.742

Review 3.  Total pelvic exenteration for pelvic recurrence after advanced epithelial ovarian cancer--A case report and literature review.

Authors:  N Bacalbașa; I Bălescu
Journal:  J Med Life       Date:  2015 Jul-Sep

4.  Pelvic exenteration for recurrent cervical cancer: ten-year experience at National Cancer Center in Korea.

Authors:  Heon Jong Yoo; Myong Cheol Lim; Sang-Soo Seo; Sokbom Kang; Chong Woo Yoo; Joo-Young Kim; Sang-Yoon Park
Journal:  J Gynecol Oncol       Date:  2012-09-19       Impact factor: 4.401

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.